Mergers and acquisitions

#Ageing #Mergers and acquisitions #Rare disease #Sentynl Therapeutics

Sentynl buys treatment for rare ageing disease

Biopharmaceutical company Sentynl Therapeutics has acquired Eiger Biopharmaceuticals’ approved treatment for the rare disease progeria. Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), in young people 12 months of age and older, are ultra-rare, fatal, genetic premature ageing diseases that accelerate mortality in young patients. Eiger’s… Read More

#Business & Investment #News

business deal
#Drug discovery #Funding #Mergers and acquisitions #Obesity #Oncology

Reflections from LSX World Congress 

DDW Editor Reece Armstrong and Multimedia Editor Megan Thomas attended LSX World Congress from 29-30 April in London, UK. Having attended a range of sessions and spoken to industry attendees, they reflect on the biotech arm of the event.   Day One  The morning of LSX was punctuated by investment sessions… Read More

#Exclusive Content #News

#Breast cancer #Clinical trials #Covid-19 #DDW Highlights podcast #FDA #lcohol Use Disorder #Mergers and acquisitions #Psychedelics

New DDW Highlights podcast: 2 April 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In another busy week for drug discovery and development, we have seen the FDA… Read More

#News

#Alcohol Use Disorder #Breast cancer #Clinical trials #Covid-19 #FDA #Mergers and acquisitions #Psychedelics

This week in drug discovery (25-29 March) 

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More

#News

Novo Nordisk head office
#Cardior Pharmaceuticals #Cardiovascular disease #Mergers and acquisitions #Novo Nordisk

Novo Nordisk acquires cardiovascular therapies developer

Novo Nordisk has acquired Cardior Pharmaeuticals for up to €1.025 billion, including an upfront payment and additional payments if certain milestones are achieved. Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. The company seeks to advance… Read More

#Business & Investment #News

#Akari Therapeutics #Antibody drug conjugate (ADC) #Mergers and acquisitions #Peak Bio #Stem cells

Akari Therapeutics and Peak Bio announce merger

Biotechnology company Akari Therapeutics and biopharmaceutical company Peak Bio have announced a definitive agreement to merge as equals in an all-stock transaction. The combined entity will operate as Akari Therapeutics, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the… Read More

#Business & Investment #News

#Clinical Microbiomics #DNASense #Mergers and acquisitions #Microbiome #RNA sequencing

Clinical Microbiomics makes third acquisition in 18 months

Clinical Microbiomics has acquired DNASense, a Danish microbiome clinical research organisation (CRO) specialised in long-read DNA and RNA sequencing technologies and bioinformatics. The acquisition adds long-read DNA and RNA sequencing technologies to Clinical Microbiomics’ multi-omics technologies for the microbiome field. H Bjørn Nielsen, CSO of Clinical Microbiomics, said: “DNASense is… Read More

#Business & Investment #News

#Bristol Myers Squibb #Mergers and acquisitions #Radiopharmaceuticals #RayzeBio

Bristol Myers Squibb buys radiopharmaceuticals company

Bristol Myers Squibb has completed its acquisition of RayzeBio for approximately $4.1 billion, adding radiopharmaceutical therapeutics (RPTs) to its pipeline. Chris Boerner, Chief Executive Officer, Bristol Myers Squibb, said: “By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS’s growth in the… Read More

#Business & Investment #News

business deal
#Acquisition #Biotech #Drug development #Investment #Mergers and acquisitions

Novo Holdings acquires Catalent for $16.5 billion 

Catalent and Novo Holdings, a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation, have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion.  Novo Holdings will acquire… Read More

#News

#Gene therapy #Kyowa Kirin #Mergers and acquisitions #Orchard Therapeutics

Kyowa Kirin completes acquisition of Orchard Therapeutics

Japan-based pharma company Kyowa Kirin has successfully completed the acquisition of gene therapy developer Orchard Therapeutics. Orchard Therapeutics’ portfolio comprises Libmeldy (atidarsagene autotemcel), which is intended for the treatment of eligible patients with early-onset metachromatic leukodystrophy (MLD), a rare and life-threatening inherited disease of the body’s metabolic system. Libmeldy is… Read More

#Business & Investment #News

Merck HQ
#Harpoon Therapeutics #Immunotherapy #Merck #Mergers and acquisitions #Oncology

Merck continues to boost oncology pipeline through acquisitions

Merck (MSD), through a subsidiary, has agreed to acquire immunotherapy company Harpoon Therapeutics for $680 million. The acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumours. The announcement follows the news that Merck agreed… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Mergers and acquisitions #SandboxAQ

SandboxAQ acquisition to accelerate AI simulation

SandboxAQ has acquired Good Chemistry, a computational chemistry company that leverages AI, quantum and other advanced technologies to accelerate drug discovery. Good Chemistry, which spun out of 1Qbit in 2021, is SandboxAQ's second acquisition and its first in the AI simulation sector. "Good Chemistry's software and existing partnerships will enable… Read More

#Business & Investment #News

GSK offices
#Asthma #GSK #Mergers and acquisitions #Monoclonal antibodies #Respiratory

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications. Read More

#Business & Investment #News

#AbCheck #Ampersand Biomedicines #Antibodies #Mergers and acquisitions

Ampersand Biomedicines acquires antibody discovery company

Ampersand Biomedicines has announced the acquisition of antibody discovery technology company AbCheck, previously a wholly-owned subsidiary of Affimed. Ampersand Biomedicines launched out of Flagship Pioneering in March 2023. The company hopes the addition of AbCheck’s discovery platform will enable cost-effective and strategic acceleration of its own Address, Navigate, Determine (AND)… Read More

#Business & Investment #News

#Business #Centricity Research #Lucas Research #Mergers and acquisitions

Clinical research business continues to expand in US

Centricity Research has acquired North Carolina-based Lucas Research, making it the fifth clinical research company to join Centricity since it launched in November 2021. With this acquisition, Centricity now has more than 35 clinical research sites, reaching 8.5 million geographically and ethnically-diverse patients. The company has 155 investigators who perform… Read More

#Business & Investment #News

#Antibody-based therapeutics #Artificial intelligence (AI) #CAR-T #Mergers and acquisitions #Microbiome #Partnership #Proteomics

Drug discovery deals highlight key growth areas

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Thermo Fisher Scientific acquires proteomics experts Olink Thermo Fisher Scientific will acquire proteomics company Olink in… Read More

#Business & Investment #News